Media ReleasesImmutep

View All Immutep News

Immutep - Leading Oncologists appointed to Clinical Advisory Board

SYDNEY, AUSTRALIA – 18 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company’s Clinical Advisory Board (CAB).  

The CAB serves as a strategic resource to Immutep as the Company continues to advance its pipeline of LAG3 programs, including combination therapy programs for lead product candidate eftilagimod alpha (“efti” or “IMP321”).

Immutep CSO & CMO, Dr. Frederic Triebel, commented: “We are privileged to have a group of leading oncologists on our Clinical Advisory Board and are pleased to welcome several new members. The CAB’s experience in the development of ground-breaking new cancer therapies will be invaluable as we look to advance efti into important late-stage development programs. In the coming months, we expect the CAB will particularly focus on our programs addressing metastatic breast and non-small cell lung carcinomas.”

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.